Let’s Talk Nutrition With Nico Episode 4: When Headlines and Data Disagree

The fourth episode of "Let's Talk Nutrition with Nico," a collaborative video series between Lana Pine of The Educated Patient and Nicholas Saraceno of Nutritional Outlook, examines media literacy around nutrition science. Saraceno highlights a recent Nutritional Outlook video interview with Harry Rice, PhD, vice president of regulatory and scientific affairs at the Global Organization for EPA and DHA Omega-3s (GOED), who pushed back on 2 recent studies that received negative media attention for concluding omega-3s "didn't work" for cognitive decline and traumatic brain injury.

Rice argued that both studies had meaningful limitations, including the use of cognitive assessment tools not well suited to the populations being studied, and that headlines rarely capture that nuance.

Saraceno also discusses how the same conversation touched on the strength of the evidence base for omega-3s and cardiovascular health, which Rice described as considerably more robust than the cognitive health data. The episode closes with a discussion of why this distinction matters for both manufacturers making substantiation decisions and for consumers trying to make sense of conflicting news coverage.

A transcript of Pine's and Saraceno's conversation can be found below.

Lana Pine: I'm Lana Pine, senior editor of The Educated Patient, and welcome to our fourth episode of "Let's Talk Nutrition with Nico." I'm joined as always by Nico Saraceno, senior editor of NO. Good to see you, Nico.

Nicholas Saraceno: Good to see you too, Lana. I’ve gotta say—this one's a bit different from our last few episodes.

Pine: How so?

Saraceno: Well, it's less about 1 ingredient or 1 health condition, and more about how nutrition science actually gets communicated to people. I recently spoke with Harry Rice,¹ who's vice president of regulatory and scientific affairs at GOED, the Global Organization for EPA and DHA Omega-3s. We were talking mostly about supply chain issues, but he brought up something that I think your readers would find really relevant.

Pine: What was that?

Saraceno: He mentioned 2 studies that received a lot of negative press recently, one on cognitive decline and Alzheimer's disease,² and another on traumatic brain injury.³ Both concluded that omega-3s didn't show a benefit. And the headlines pretty much ran with that at face value.

Pine: Hmm, I’m waiting for the other shoe to drop. He didn't think that was the whole picture, did he?

Saraceno: Right. He wasn't disputing the results themselves; rather, he said the conclusions the researchers drew were fair given how the studies were designed. But he pointed out real limitations. In the Alzheimer's study specifically, he said the cognitive assessments used weren't really appropriate for the population being studied or for tracking how the condition was progressing. So the tool itself may not have been sensitive enough to pick up a real effect, even if one existed.

Pine: That's a pretty important distinction that a headline just can't capture.

Saraceno: Exactly, and that's really the point of this episode. A study can be technically well conducted and still have a limitation that changes how much weight the conclusion deserves. But by the time it hits social media, it's just "omega-3s don't work," full stop.

Pine: From The Educated Patient's side, we hear this constantly. Patients see 1 headline and it shapes what they ask their doctor, sometimes more than the actual guidance does.

Saraceno: That tracks with what Rice said too. He mentioned that GOED has to actively decide which stories are getting enough traction that they need to step in with talking points for their members. It's not that they respond to everything, it's that some stories get picked up widely enough that member companies start fielding questions from customers.

Pine: Did he draw any comparison to where the evidence actually is strong?

Saraceno: He did, and I thought this was a useful contrast. He was pretty direct in stating that the evidence for omega-3s and heart health is, in his words, “incredibly strong,” much stronger than for most areas of cognitive health, where he said the science is still emerging, though stronger in some areas than others. So it's not that all omega-3 research is shaky, it's that the strength of evidence really depends on which health outcome you're asking about.

Pine: That seems like a good takeaway for consumers: the same ingredient can have really solid evidence for one use and much thinner evidence for another.

Saraceno: Right, and for manufacturers, it's a reminder to be precise about which claim you're actually making and what it's backed by, rather than letting the ingredient's overall reputation carry an application the data doesn't fully support yet. I’ll also be throwing the links to the studies in the body of the video for everyone to check them out for themselves.

Pine: This was a good one, Nico. It's a nice reminder for our readers to slow down before reacting to a headline.

Saraceno: Agreed. Thanks for having me, Lana. See you next time!

References

1. Saraceno N. Modernizing dietary supplement regulation. Nutritional Outlook. June 26, 2026. Accessed July 10, 2026. https://www.nutritionaloutlook.com/view/modernizing-dietary-supplement-regulation

2. Liao ZB, Hu ZC, Zeng GH, et al; Alzheimer's Disease Neuroimaging Initiative. The association between omega-3 supplementation and cognitive decline in older adults. J Prev Alzheimers Dis. 2026;13(6):100569. doi:10.1016/j.tjpad.2026.100569

3. Karakaya E, Berber B, Eskiocak O, et al. Eicosapentaenoic acid reprograms cerebrovascular metabolism and impairs repair after brain injury, with relevance to chronic traumatic encephalopathy. Cell Rep. Published online March 25, 2026. doi:10.1016/j.celrep.2026.11713